PTPRT and non-small cell lung carcinoma: For the NSCLC, a marginally significantly better prognosis was observed in PTPRT mutant subgroup in both univariate (Log‐rank test p = 0.089; Figure 7E) and multivariate analyses (HR: 0.73, 95% CI: 0.45–1.16, p = 0.121; Figure 7F).